This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.